Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NLS Pharmaceutics AG (NLSPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NLSPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1687887 |
Shares Outstanding - | Shares Floating 1687887 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focused on developing innovative therapies for patients with rare and complex central nervous system disorders.
Core Business Areas
- Lead Product Candidate - Quilienceu00ae: A formulation of mazindol for the treatment of narcolepsy. Phase 3 trials ongoing.
- Second product candidate - Nolazolu00ae: Controlled-release formulation of mazindol for the treatment of ADHD. Preclinical.
Leadership and Structure
Alexander Zwyer is the Chief Executive Officer. The company operates with a Board of Directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- Quilienceu00ae: A formulation of mazindol for the treatment of narcolepsy. Currently in Phase 3 clinical trials. If approved, market share depends on clinical trial outcomes and marketing efforts. Competitors include Jazz Pharmaceuticals (XLRB) with Xyrem/Xywav and Avadel Pharmaceuticals (AVDL) with Lumryz.
- Nolazolu00ae: A controlled-release formulation of mazindol for the treatment of ADHD. Preclinical stage. Market share potential depends on clinical trial success and regulatory approvals. Competitors are varied and well established including Teva Pharmaceutical (TEVA), Johnson & Johnson (JNJ), and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive and highly regulated, with a focus on research and development of new drugs and therapies. NLS Pharmaceutics AG operates within the niche market of CNS disorders.
Positioning
NLS Pharmaceutics AG is a smaller player focused on repurposing mazindol for narcolepsy and ADHD. Their success depends on successful clinical trials and regulatory approval. Competitive advantages would depend on efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The Narcolepsy and ADHD market are substantial; Narcolepsy at 3.1B in 2023 and ADHD expected to be ~25B by 2030. NLS Pharmaceutics AG's positioning within these markets depends on the success of Quilienceu00ae and Nolazolu00ae.
Upturn SWOT Analysis
Strengths
- Focus on CNS disorders
- Repurposing an existing drug (mazindol)
- Potential for orphan drug designation
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small company size
Opportunities
- Positive clinical trial results
- FDA approval for Quilienceu00ae and Nolazolu00ae
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- JAZZ
- AVDL
- TEVA
- JNJ
- LLY
Competitive Landscape
NLS Pharmaceutics AG faces significant competition from established pharmaceutical companies with greater resources and market presence. Success hinges on demonstrating superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the development stage of the company.
Future Projections: Future growth projections depend on the success of Quilienceu00ae and Nolazolu00ae clinical trials and regulatory approvals. Analyst estimates are highly variable.
Recent Initiatives: Focus on advancing Quilienceu00ae through Phase 3 clinical trials and continuing preclinical development of Nolazolu00ae.
Summary
NLS Pharmaceutics AG is a high-risk, high-reward biopharmaceutical company. Their success is heavily dependent on the outcomes of their clinical trials. Positive results for Quilienceu00ae would be a significant catalyst, but clinical trial failures would significantly impact the company negatively. They need to secure partnerships and funding to support their clinical development programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in NLS Pharmaceutics AG is highly speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.